Evodiamine release from interlinked porous polycaprolactone scaffold for cancer therapy
Process Biochemistry, ISSN: 1359-5113, Vol: 140, Page: 1-9
2024
- 1Citations
- 10Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Target drug delivery for therapeutic pharmaceuticals in a carcinogenic environment is becoming more popular because of its benefits, such as avoiding systemic adverse effects, high productivity and low-cost competence. Herein, in this study Evodiamine-albumin nanoparticles (EANPs) were incorporated into 3D porous polycaprolactone (PCL) scaffolds for sustained release, aiming to evaluate their potential as an effective and improved treatment for cervical cancer. Morphological and physicochemical analyses confirmed successful nanoparticle integration and drug amorphization. EANP-loaded scaffolds exhibited controlled drug release for 8 days, with increasing concentrations inducing dose-dependent cytotoxicity and apoptosis in HeLa cancer cells. These findings suggest EANP-loaded PCL scaffolds hold significant potential for improved cervical cancer treatment through sustained drug delivery and enhanced efficacy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1359511324000400; http://dx.doi.org/10.1016/j.procbio.2024.01.028; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85185531686&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S1359511324000400; https://dx.doi.org/10.1016/j.procbio.2024.01.028
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know